vs

Side-by-side financial comparison of Globe Life (GL) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

Globe Life is the larger business by last-quarter revenue ($1.6B vs $961.0M, roughly 1.6× DENTSPLY SIRONA Inc.). Globe Life runs the higher net margin — 17.3% vs -15.2%, a 32.5% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs 5.3%). Over the past eight quarters, Globe Life's revenue compounded faster (4.1% CAGR vs 0.4%).

Globe Life Inc. (GL) is an American financial services holding company listed on the New York Stock Exchange which operates through its wholly owned subsidiaries providing life insurance, annuity, and supplemental health insurance products. The company is based in McKinney, Texas.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

GL vs XRAY — Head-to-Head

Bigger by revenue
GL
GL
1.6× larger
GL
$1.6B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+0.8% gap
XRAY
6.2%
5.3%
GL
Higher net margin
GL
GL
32.5% more per $
GL
17.3%
-15.2%
XRAY
Faster 2-yr revenue CAGR
GL
GL
Annualised
GL
4.1%
0.4%
XRAY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
GL
GL
XRAY
XRAY
Revenue
$1.6B
$961.0M
Net Profit
$270.5M
$-146.0M
Gross Margin
46.1%
Operating Margin
-14.5%
Net Margin
17.3%
-15.2%
Revenue YoY
5.3%
6.2%
Net Profit YoY
6.3%
66.0%
EPS (diluted)
$3.39
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GL
GL
XRAY
XRAY
Q1 26
$1.6B
Q4 25
$1.5B
$961.0M
Q3 25
$1.5B
$904.0M
Q2 25
$1.5B
$936.0M
Q1 25
$1.5B
$879.0M
Q4 24
$1.5B
$905.0M
Q3 24
$1.5B
$951.0M
Q2 24
$1.4B
$984.0M
Net Profit
GL
GL
XRAY
XRAY
Q1 26
$270.5M
Q4 25
$266.1M
$-146.0M
Q3 25
$387.8M
$-427.0M
Q2 25
$252.7M
$-45.0M
Q1 25
$254.6M
$20.0M
Q4 24
$255.2M
$-430.0M
Q3 24
$303.0M
$-494.0M
Q2 24
$258.4M
$-4.0M
Gross Margin
GL
GL
XRAY
XRAY
Q1 26
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
26.1%
52.1%
Q2 24
23.3%
51.9%
Operating Margin
GL
GL
XRAY
XRAY
Q1 26
Q4 25
21.7%
-14.5%
Q3 25
31.5%
-24.1%
Q2 25
21.2%
-13.7%
Q1 25
21.4%
7.2%
Q4 24
21.3%
-56.2%
Q3 24
26.3%
-48.6%
Q2 24
23.5%
5.1%
Net Margin
GL
GL
XRAY
XRAY
Q1 26
17.3%
Q4 25
17.5%
-15.2%
Q3 25
25.6%
-47.2%
Q2 25
17.1%
-4.8%
Q1 25
17.2%
2.3%
Q4 24
17.4%
-47.5%
Q3 24
20.8%
-51.9%
Q2 24
17.9%
-0.4%
EPS (diluted)
GL
GL
XRAY
XRAY
Q1 26
$3.39
Q4 25
$3.28
$-0.74
Q3 25
$4.73
$-2.14
Q2 25
$3.05
$-0.22
Q1 25
$3.01
$0.10
Q4 24
$3.00
$-2.09
Q3 24
$3.44
$-2.46
Q2 24
$2.83
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GL
GL
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$183.8M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$6.1B
$1.3B
Total Assets
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GL
GL
XRAY
XRAY
Q1 26
$183.8M
Q4 25
$314.7M
$326.0M
Q3 25
$62.8M
$363.0M
Q2 25
$116.7M
$359.0M
Q1 25
$134.1M
$398.0M
Q4 24
$85.0M
$272.0M
Q3 24
$100.5M
$296.0M
Q2 24
$100.6M
$279.0M
Total Debt
GL
GL
XRAY
XRAY
Q1 26
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Stockholders' Equity
GL
GL
XRAY
XRAY
Q1 26
$6.1B
Q4 25
$6.0B
$1.3B
Q3 25
$5.7B
$1.5B
Q2 25
$5.4B
$2.0B
Q1 25
$5.4B
$2.0B
Q4 24
$5.3B
$1.9B
Q3 24
$4.6B
$2.5B
Q2 24
$5.2B
$3.1B
Total Assets
GL
GL
XRAY
XRAY
Q1 26
Q4 25
$30.8B
$5.4B
Q3 25
$30.5B
$5.7B
Q2 25
$29.8B
$6.1B
Q1 25
$29.7B
$6.0B
Q4 24
$29.1B
$5.8B
Q3 24
$29.6B
$6.6B
Q2 24
$28.3B
$6.9B
Debt / Equity
GL
GL
XRAY
XRAY
Q1 26
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GL
GL
XRAY
XRAY
Operating Cash FlowLast quarter
$101.0M
Free Cash FlowOCF − Capex
$60.0M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GL
GL
XRAY
XRAY
Q1 26
Q4 25
$350.6M
$101.0M
Q3 25
$306.0M
$79.0M
Q2 25
$307.9M
$48.0M
Q1 25
$431.9M
$7.0M
Q4 24
$336.9M
$87.0M
Q3 24
$340.6M
$141.0M
Q2 24
$374.1M
$208.0M
Free Cash Flow
GL
GL
XRAY
XRAY
Q1 26
Q4 25
$330.1M
$60.0M
Q3 25
$208.7M
$40.0M
Q2 25
$295.0M
$16.0M
Q1 25
$420.1M
$-12.0M
Q4 24
$321.9M
$36.0M
Q3 24
$311.3M
$98.0M
Q2 24
$356.5M
$156.0M
FCF Margin
GL
GL
XRAY
XRAY
Q1 26
Q4 25
21.7%
6.2%
Q3 25
13.8%
4.4%
Q2 25
19.9%
1.7%
Q1 25
28.4%
-1.4%
Q4 24
22.0%
4.0%
Q3 24
21.4%
10.3%
Q2 24
24.8%
15.9%
Capex Intensity
GL
GL
XRAY
XRAY
Q1 26
Q4 25
1.3%
4.3%
Q3 25
6.4%
4.3%
Q2 25
0.9%
3.4%
Q1 25
0.8%
2.2%
Q4 24
1.0%
5.6%
Q3 24
2.0%
4.5%
Q2 24
1.2%
5.3%
Cash Conversion
GL
GL
XRAY
XRAY
Q1 26
Q4 25
1.32×
Q3 25
0.79×
Q2 25
1.22×
Q1 25
1.70×
0.35×
Q4 24
1.32×
Q3 24
1.12×
Q2 24
1.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GL
GL

Life premium$853.2M55%
Health premium$416.9M27%
Other$289.5M19%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons